Abstract 319 Table 2

Molecular characteristics & target therapy

PatientAgePathologyMutationTarget therapy
1 77 Clear cell endometrial carcinoma mut. L755S ERBB2 Evaluable for Afatinib
2 67 High grade serous ovarian carcinoma Mut. V600E BRAF Ongoing Dabrafenib + trametinib
3 54 Squamous cervical carcinoma HPV at ISH Ongoing Atezolizumab + anti ICOS
4 52 Endometrial carcinosarcoma MSI Evaluable for Atezolizumab
5 71 Endometrial carcinoma Mut R88Q PI3KCA Evaluable for Everolimus + exemestane
6 30 Mucinous cervical adenocarcinoma splice site (134+1G>T) PTEN Evaluable for Everolimus
7 60 Low grade serous ovarian carcinoma Mut. V600E BRAF Ongoing Trametinib
8 41 Squamous cervical carcinoma Mut p.E545K PI3KCA Ongoing Alpelisib
9 71 Endometrioid Endometrial carcinoma Mut. Q546P PI3KCA Evaluable for Alpelisib
10 39 Neuroendocrine cervical cancer Mut p.E545K PI3KCA Ongoing Alpelisib